A Randomized Multicenter Study to Compare Two Types of Transplant in Adult Patients With Hematologic Malignancies

A Randomized Multicenter Study Comparing Unrelated Umbilical-cord Blood Transplant Versus Human Leukocyte Antigen (HLA)-Haploidentical Related Hematopoietic Stem Cell Transplant for Adult Patients With Hematologic Malignancies

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02386332

Enrollment

206

Registered

2015-03-11

Start date

2015-03-31

Completion date

2020-03-31

Last updated

2015-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematologic Malignancies

Brief summary

This is an open-label, prospective, observational, multicenter, randomized study to compare the efficacy between unrelated umbilical cord blood transplantation (UCBT) and HLA-haploidentical related hematopoietic stem cell transplantation ,after myeloablative conditioning for adult patients with hematologic malignancies.

Interventions

PROCEDUREtransplantation

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Inclusion criteria

1. Age: subjects ≥ 18 and ≤ 55 years old. 2. Patients without suitable matched related donor 3. Diagnosed with acute leukemia or myelodysplastic syndrome in which allogeneic transplantation is considered the most potentially curative therapeutic option. 4. Written consent form signed.

Exclusion criteria

* Performance status: Eastern Cooperative Oncology Group(ECOG) score \>2 * Prior allogenic hematopoietic stem cell transplant * Left-ventricular ejection fraction at rest \< 45%, uncontrolled arrhythmias or symptomatic heart failure. * Diffusing capacity (DLCO) and/or forced vital capacity (FVC) \< 39% of predicted values or symptomatic pulmonary disease * Altered liver function tests (total bilirubin \> 2 mg/dL and/or alanine aminotransferase, aspartate aminotransferase , and or active hepatitis or cirrhosis. * Serum creatinine \> 2 mg/dL or estimated creatinine clearance \< 50 mL/min * Evidence of uncontrolled bacterial, viral or fungal infection prior to the conditioning regimen * Serious diseases that prevent patients from receiving chemotherapy treatments. * Concomitant neoplasms. * Pregnancy or breast-feeding. * Any other medical, surgical or psychiatric condition that is considered by the attending and/or medical team as a contraindication for intensive treatment

Design outcomes

Primary

Measure	Time frame
Disease-Free Survival (DFS)	2 years

Contacts

Primary ContactMiguel A Sanz, MD

msanz@uv.es+34.961.245875

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026